Literature DB >> 22560135

Clinical features and practical diagnosis of bullous pemphigoid.

Enno Schmidt1, Rocco della Torre, Luca Borradori.   

Abstract

Bullous pemphigoid (BP) represents the most common autoimmune subepidermal blistering disease. BP typically affects the elderly and is associated with significant morbidity. It has usually a chronic course with spontaneous exacerbations. The cutaneous manifestations of BP can be extremely protean. While diagnosis of BP in the bullous stage is straightforward, in the non-bullous stage or in atypical variants of BP signs and symptoms are frequently non-specific with eg, only itchy excoriated, eczematous, papular and/or urticarial lesions that may persist for several weeks or months. Diagnosis of BP critically relies on immunopathologic examinations including direct immunofluorescence microscopy and detection of serum autoantibodies by indirect immunofluorescence microscopy or BP180-ELISA.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22560135     DOI: 10.1016/j.iac.2012.04.002

Source DB:  PubMed          Journal:  Immunol Allergy Clin North Am        ISSN: 0889-8561            Impact factor:   3.479


  17 in total

1.  Assessment of the Prevalence of Mucosal Involvement in Bullous Pemphigoid.

Authors:  Khalaf Kridin; Reuven Bergman
Journal:  JAMA Dermatol       Date:  2019-02-01       Impact factor: 10.282

Review 2.  Autoimmune Subepidermal Bullous Diseases of the Skin and Mucosae: Clinical Features, Diagnosis, and Management.

Authors:  Kyle T Amber; Dedee F Murrell; Enno Schmidt; Pascal Joly; Luca Borradori
Journal:  Clin Rev Allergy Immunol       Date:  2018-02       Impact factor: 8.667

3.  [85-year-old male with cutaneous blisters : Preparation for the medical specialist examination: Part 25].

Authors:  Mareike Witte; Enno Schmidt; Ralf Ludwig
Journal:  Hautarzt       Date:  2018-11       Impact factor: 0.751

Review 4.  Subepidermal autoimmune bullous diseases: overview, epidemiology, and associations.

Authors:  Khalaf Kridin
Journal:  Immunol Res       Date:  2018-02       Impact factor: 2.829

5.  Localized pretibial bullous pemphigoid arising in a patient on pembrolizumab for metastatic melanoma.

Authors:  Kyle T Amber; Manuel Valdebran; Yuxin Lu; Sebastien De Feraudy; Kenneth G Linden
Journal:  J Dtsch Dermatol Ges       Date:  2018-02-01       Impact factor: 5.584

Review 6.  Bullous pemphigoid in a 3-month-old infant: case report and literature review of this dermatosis in childhood.

Authors:  Eugenio Galdino de Mendonça Reis-Filho; Tainah de Almeida Silva; Luiza Helena de Lima Aguirre; Carmelia Matos Santiago Reis
Journal:  An Bras Dermatol       Date:  2013 Nov-Dec       Impact factor: 1.896

7.  Lokalisiertes prätibiales bullöses Pemphigoid bei einer Patientin unter Pembrolizumab-Therapie wegen eines metastasierten Melanoms.

Authors:  Kyle T Amber; Manuel Valdebran; Yuxin Lu; Sebastien De Feraudy; Kenneth G Linden
Journal:  J Dtsch Dermatol Ges       Date:  2018-02       Impact factor: 5.584

8.  Seborrheic pemphigoid.

Authors:  Lucia Lourdes O Castro-Forés; Jamaine Melisse L Cruz; Maria Jasmin J Jamora; Katrina M Canlas-Estrella
Journal:  JAAD Case Rep       Date:  2016-02-27

9.  Correlation between IL36α and IL17 and Activity of the Disease in Selected Autoimmune Blistering Diseases.

Authors:  Agnieszka Żebrowska; Anna Woźniacka; Katarzyna Juczyńska; Kamila Ociepa; Elżbieta Waszczykowska; Izabela Szymczak; Rafał Pawliczak
Journal:  Mediators Inflamm       Date:  2017-05-10       Impact factor: 4.711

10.  Probable fondaparinux-associated bullous hemorrhagic dermatosis.

Authors:  Catherine Anne Lovatt; Wen Qing Wendy Ye; Haroon Yousuf
Journal:  CMAJ       Date:  2021-05-31       Impact factor: 8.262

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.